459 related articles for article (PubMed ID: 25734630)
1. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?
Bos AC; van Holsbeke C; de Backer JW; van Westreenen M; Janssens HM; Vos WG; Tiddens HA
PLoS One; 2015; 10(3):e0118454. PubMed ID: 25734630
[TBL] [Abstract][Full Text] [Related]
2. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
3. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
[TBL] [Abstract][Full Text] [Related]
4. Inhaled aztreonam lysine: an evidence-based review.
Hutchinson D; Barclay M; Prescott WA; Brown J
Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
[TBL] [Abstract][Full Text] [Related]
6. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
[TBL] [Abstract][Full Text] [Related]
7. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
8. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
9. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2010 Aug; 4(4):435-44. PubMed ID: 20658904
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
[TBL] [Abstract][Full Text] [Related]
11. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
Pesaturo KA; Horton ER; Belliveau P
Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
[TBL] [Abstract][Full Text] [Related]
12. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics.
Hasan MA; Lange CF
J Aerosol Med; 2007; 20(3):282-93. PubMed ID: 17894535
[TBL] [Abstract][Full Text] [Related]
13. Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?
Bos AC; Mouton JW; van Westreenen M; Andrinopoulou ER; Janssens HM; Tiddens HAWM
J Antimicrob Chemother; 2017 Dec; 72(12):3435-3442. PubMed ID: 29029057
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
Hansen C; Skov M
Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
[TBL] [Abstract][Full Text] [Related]
16. Effect of Inspiratory Maneuvers on Lung Deposition of Tobramycin Inhalation Powder: A Modeling Study.
Meerburg JJ; Andrinopoulou ER; Bos AC; Shin H; van Straten M; Hamed K; Mastoridis P; Tiddens HAWM
J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):61-72. PubMed ID: 32073919
[No Abstract] [Full Text] [Related]
17. The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.
Heirali AA; Acosta N; Storey DG; Workentine ML; Somayaji R; Laforest-Lapointe I; Leung W; Quon BS; Berthiaume Y; Rabin HR; Waddell BJ; Rossi L; Surette MG; Parkins MD
J Cyst Fibros; 2019 Nov; 18(6):829-837. PubMed ID: 30857926
[TBL] [Abstract][Full Text] [Related]
18. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
19. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
Wainwright CE; Quittner AL; Geller DE; Nakamura C; Wooldridge JL; Gibson RL; Lewis S; Montgomery AB
J Cyst Fibros; 2011 Jul; 10(4):234-42. PubMed ID: 21441078
[TBL] [Abstract][Full Text] [Related]
20. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
